(Q36582709)

15 August 2017

title

Risk versus benefit considerations for the beta(2)-agonists (English)

1 reference

15 August 2017

H William Kelly

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

26

1 reference

15 August 2017

issue

9 Pt 2

1 reference

15 August 2017

page(s)

164S-74S

1 reference

Investigation into use of drugs preceding death from asthma

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Regular inhaled beta-agonist treatment in bronchial asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Levalbuterol: pharmacologic properties and use in the treatment of pediatric and adult asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Comparison of R-, S-, and RS-albuterol interaction with human beta 1- and beta 2-adrenergic receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Single-isomer beta-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

(S)-Albuterol activates pro-constrictory and pro-inflammatory pathways in human bronchial smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Hyperresponsiveness of the airways following exposure of guinea-pigs to racemic mixtures and distomers of beta 2-selective sympathomimetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Effects of (R)- and (S)-isomers of beta-adrenergic agonists on eosinophil response to interleukin-5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Rapid onset of tolerance to beta-agonist bronchodilation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Increased bronchial hyperresponsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonists reflecting a real deterioration of the disease in allergic asthmatic patients? A comparison between short-acting and long-acting beta2-agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Inhaled beta-2 adrenergic receptor agonists and primary cardiac arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Inhaled short acting beta agonist use in COPD and the risk of acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Effects of S-salbutamol on human isolated bronchus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Effect of single doses of S-salbutamol, R-salbutamol, racemic salbutamol, and placebo on the airway response to methacholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Meta-analysis: respiratory tolerance to regular beta2-agonist use in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Regular inhaled beta agonist in asthma: effects on exacerbations and lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

The use of beta-agonists and the risk of death and near death from asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Serious asthma exacerbations in asthmatics treated with high-dose formoterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Beta-agonists and asthma: too much of a good thing?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

beta-Adrenergic receptor polymorphisms and response to salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.26.9PART2.164S

10.1592/PHCO.26.9PART2.164S

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference